摘要
有研究证实部分 COPD急性加重期痰液嗜酸粒细胞（eosinophils,EOS）增加,对此类患者应用糖皮质激素治疗,能促进肺功能恢复、缩短病程并降低治疗失败率。然而,在日常临床实践中,诱导痰项目存在技术要求高、检测有效性低、部分患者不能耐受等情况。所以,探讨血 EOS和痰 EOS之间的相关性,选择血 EOS计数作为一种标志物,评估 COPD患者的激素治疗反应,可能更实用。本文就这些方面作一综述。
As the evidence began to accumulate,sputum Eosinophil increase in some patients during acute exacerbations of chronic obstructive pulmonary disease.And glucocorticoids therapy has help to such patients,as like facilitating lung function recovery.Decreasing course of the disease and reducing treatment failure rate.However,in daily clinical practice,induced sputum project has some weakpoints, such as more technically affairs,low efficiency of the test,some patients are intolerable and so on. Therefore,it may be more practical that selecting blood eosinophils count as a biomarker of response to glucocorticoids in patients with COPD by exploring the link between blood eosinophils and sputum eosinophils.In this article,we will make an overview on these.
出处
《国际呼吸杂志》
2016年第12期948-951,共4页
International Journal of Respiration
